Introduction
derive from the local fibroblast pool; however, epithelial, endothelial, hematopoietic cells, or 80 pericytes can also differentiate into myofibroblasts [16] . Nevertheless, the chain of events 81 leading to intestinal fibrosis is insufficiently understood. 82
Studying the pathophysiology of intestinal fibrosis has been limited by the lack of a bona fide 83 animal model. Chronic dextran sodium sulfate (DSS) colitis is frequently used as a fibrosis 84 model [17, 18] , even though key aspects of CD associated intestinal fibrosis, such as 85 occlusion of the intestinal lumen are not observed in this model. Recently, we established and 86 characterized a murine heterotopic transplant model, where small intestinal sections are 87 transplanted into the neck fold of recipient mice [19, 20] . In the transplanted sections, the 88 lumen progressively occludes, accompanied by expression of TGF-β and α-SMA, as well as 89 collagen deposition in the extracellular matrix. In this model, we previously demonstrated that 90 pirfenidone, an anti-inflammatory and anti-fibrotic drug approved for the treatment of 91 idiopathic pulmonary fibrosis, was able to reduce fibrosis [20] . production was shown to be increased in the airways of patients with chronic obstructive 103 pulmonary disease (COPD) and correlated with the degree of neutrophilic infiltration [35] . 25-6 HC can be further hydroxylated to di-hydroxy cholesterols (e.g. 7α, 25-HC) which have been 105 shown to act as chemoattractants for cells of the adaptive and innate immune system [36, 37] . 106
Recently, CH25H expression was shown to be upregulated in primary lung fibroblasts in 107 response to activated eosinophils, suggesting CH25H activation in chronic lung diseases 108 including COPD [38] . Pro-fibrotic effects of the CH25H product 25-HC have been 109 demonstrated in vitro: In a tissue culture model using human fetal lung fibroblasts (HLF), 25-110 HC induced nuclear factor-κB (NF-κB) activation with subsequent release of TGF-β, leading 111 to myofibroblast formation, MMP-2 and 9 release, SMA expression and collagen 112 production [39] . However, the role of 25-HC in intestinal inflammation and fibrosis has not 113 been addressed. In this study, we aimed to investigate the role of the enzyme CH25H in the 114 development of intestinal fibrosis. 115 116
Results

117
CH25H mRNA expression is a marker of fibrosis in intestinal samples of CD patients 118
To test for a role of the oxysterol synthesiting enzyme CH25H in CD associated fibrosis, 119 CH25H mRNA expression was measured in human intestinal surgical samples. We 120 investigated terminal ileum samples from CD patients undergoing ileocecal resection due to 121 stenosis. Samples macroscopically affected by fibrosis were compared to the proximal ileal 122 resection margin which showed no macroscopic signs of fibrosis or inflammation. Healthy 123 tissue from cancer-free resection margins of colon adenocarcinoma patients undergoing right-124 sided hemicolectomy was used as additional control (Table 1) . Representative Sirius red 125 staining pictures illustrate increased collagen deposition in fibrotic areas of CD patients 126 ( Figure 1A ). We observed a gradual increase of CH25H mRNA expression from control 127 tissue to non-fibrotic CD tissue and to fibrotic areas from the same patients (p<0.05, Figure  128 1B). Thereby, mRNA levels of CH25H strongly correlated with the expression levels of 129 fibrosis markers including COL-1 and -3, SMA and TGF-β ( Figure 1C -F), confirming the 130 association of CH25H expression with intestinal fibrosis in the human intestine. 131
Reduced intestinal fibrosis in mice with deficient 25-hydroxycholesterol synthesis 132
To further investigate the role of CH25H in intestinal fibrosis, we investigated whether 133 absence of CH25H would reduce fibrosis in dextran sodium sulfate (DSS)-induced chronic 134 colitis, a well-established model of intestinal inflammation, typically associated with high 135 levels of intestinal fibrosis [17, 18] . For this aim, we induced chronic colon inflammation and 136 fibrosis in WT and Ch25h -/littermate mice with four cycles of 7 days 2.5% DSS in drinking 137 water followed by a 10-day recovery period with normal drinking water. Collagen deposition 138 was determined by Sirius red staining and analysis under transmission light microscopy 139 ( Figure 2A ). The collagen layer was significantly thinner in Ch25h -/mice compared to WT littermate controls ( Figure 2B , water animals: WT: 8.5 µm ± 2.1, Ch25h -/-: 8.7 µm ± 0.8 n.s., 141 DSS animals: WT: 22.4 µm ± 7.2, Ch25h -/-: 11.7 µm ± 2.6, p= 0.008). Reduced collagen 142 deposition in Ch25h knockout mice was confirmed by automated quantification of the 143 collagen layer area ( Figure 2C ). Additionally, mRNA expression levels for fibrosis markers 144 such as Tgf-β, collagen type 3 (Col-3) and Timp-1 were significantly lower in the colon of 145
Ch25h -/animals and a clear trend for lower mRNA expression of collagen type 1 (Col-1) and 146 lysyl oxidase homolog 2 (Loxl-2) in CH25H-deficient mice was found ( Figure 2D -H). 147
Expression levels of Ch25h were increased in DSS treated animals compared to water 148 controls ( Figure 2I ). 149
Of note, thinner collagen layer and lower expression levels of fibrosis markers (Tgf-β, Col-3 150
and Timp-1) upon Ch25h knockout were not due to reduced inflammation: when colon 151 inflammation was analysed in H/E stained colon sections, the histology score quantifying the 152 inflammatory infiltrate and the epithelial damage, was even higher in Ch25h -/mice compared 153 to WT littermates ( Figure 3A ). Further, macroscopic aspects of intestinal inflammation such 154 as the murine endoscopic index of colitis severity (MEICS) and spleen weight did not differ 155 between both genotypes ( Figure 3B ). In summary, in chronic DSS colitis, intestinal collagen 156 deposition was reduced in the absence of CH25H, independent from effects of CH25H 157 knockout on intestinal inflammation. 158 
Reduced intestinal fibrosis in the absence of CH25H in a heterotopic transplant model of
Recruitment of immune cells into fibrotic small intestine in wildtype and Ch25h -/-189 animals 190
To address changes in immune cells infiltrating the intestinal grafts, lamina propria 191 mononuclear cells were isolated from the grafts 7 days after surgery and an explorative mass 192 cytometry (Cytometry by Time of Flight, CyTOF) analysis with a broad marker panel (Table  193 2) was performed. Cells were automatically clustered based on similarity of surface marker 194 expression. The immune cell infiltrate was dominated by neutrophils, with a lower fraction of 195 T cells, dendritic cells, monocytes and NK cells ( Figure 6A , B). No significant differences 196 between WT and Ch25h -/animals were detected for the investigated immune cell populations 197 ( Figure 6C ). Additionally, histological analysis of IL-17 revealed no differences in IL-17 198 expression between WT and Ch25h -/grafts ( Supplementary Figure 1) . 199
To determine the location of Ch25h mRNA expression in the small intestine, RNA in situ 200 hybridization using fixed-frozen sections of intestinal grafts and freshly isolated intestines 201 was performed. Ch25h mRNA expression was detected in freshly isolated intestines from WT 202 mice and the graft at 7 days after transplantation ( Figure 7A Ch25h signal appears to be cytoplasmic with the formation of small clusters. Ch25h 204 expression was observed in fibroblasts demarcating the necrotic former mucosa layer, but 205 remains of epithelial crypts were not found in the demarcation zone. The Ch25h-expresing, 206 spindle shaped fibroblasts are arranged in a band-like fascicle with large ovoid nuclei 207 exhibiting a thinly dispersed chromatin structure and a delicate nuclear membrane without the 208 indentations typically found in the nuclei of histiocytes ( Figure 7B , arrows). In contrast, 209
Ch25h is not expressed in the inflammatory infiltrate, which mainly consists of neutrophils 210
showing characteristic segmented nuclei ( Figure 7B , double arrows). No Ch25h expressing 211 lymphocytes were found. 212
25-HC does not induce myofibroblast differentiation in vitro 213
To address direct effects of the CH25H product 25-HC on fibroblasts, we performed cell 214 culture experiments using primary murine intestinal fibroblasts using a protocol similar to a 215 previous study in a human lung fetal fibroblast cell line (HFL-1) [39] . Addition of TGF-β 216 resulted in increased α-SMA protein expression in intestinal fibroblasts. In contrast, exposure 217 to 25-HC did not affect α-SMA expression at physiological 25-HC concentrations of 0.001-218 0.1 µM ( Figure 7C) . Similarly, addition of 25-HC to 3T3 cells did not cause a significant 219 increase of α-SMA expression at concentrations of 0.001-0.1 µM ( Figure 7C ). 220 Technologies) supplemented with 10% fetal calf serum (FCS) and kept at 37°C in a 401 humidified atmosphere containing 5% CO 2 . Murine primary fibroblasts were isolated and cultured as described previously [53] . The isolated cells were cultured in 25 cm 2 culture flasks 403 (Costar, Bodenheim, Germany) with DMEM containing 10% FCS, penicillin (100 IE/mL), 404 streptomycin (100 g/mL), ciprofloxacin (8 g/mL), gentamycin (50 g/mL), and amphotericin B 405
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(1 g/mL) at 37°C in a humidified atmosphere containing 10% CO 2 . Non-adherent cells were 406 removed. Once fibroblasts reached 90% confluence, FCS free DMEM-medium was added 407 and they were starved for 24 h prior to compound treatment. Cells were stimulated by 408 treatment for 72 h with 5 ng/ml TGF-β (130-095-067, Miltenyi Biotec), 0.001-10 µM 25-HC 409 (H1015, Sigma-Aldrich) or a combination of the two compounds as indicated. 410
Statistical analysis 411
Data are presented as mean ±SEM unless otherwise indicated. Significance was assessed 412 using the Mann-Whitney U test or the unpaired t test with p < 0.05 considered statistically 413 significant (***p < 0.001, **p < 0.01, *p < 0.05). 414
Study approval 415
For patient data, written informed consent was obtained for anonymous use of patient data 416 and resected parts of human intestine according to the code of conduct for responsible use of Moderate disease 4 (50%) Severe disease 3 (37.5%) Medication (n (%)) Corticosteroids 4 (50%) Azathioprine/6-mercaptopurine 3 (37.5%) NA Anti-TNFα 1 (12.5%) Anti-IL12/23 1 (12.5%) 
